skip to Main Content
024 – Brian Pepin
Neurotech, Neurotech Podcast , Themes

Brian Pepin is the CEO and founder of Rune Labs. Brian holds an MSEE in electrical engineering from UC Berkeley and a BSEE from the University of Washington. Prior to starting Rune, Brian spent nearly five years at Verily Life Sciences.

Top 3 Takeaways

  1. It makes sense to use neuromodulation therapies for neurological and psychiatric disorders that inherently fluctuate over time.
  2. Neuromodulation data is siloed and that slows down research and translation.
  3. Closed-loop DBS can enable novel, more efficacious therapies.

Show Notes

  • [0:47] Brian’s background.
  • [1:50] The Google phase.
  • [3:10] Brian’s transition into Rune Labs.
  • [3:30] Rune in a nutshell.
  • [4:32] Unmet needs for brain diseases.
  • [5:58] Why neuromodulation instead of drugs.
  • [7:30] Need for adaptive therapies.
  • [8:53] Impact of neuromodulation in Parkinson’s Disorder.
  • [10:54] Who fits the bill for DBS.
  • [13:30] Siloed data in neuromodulation.
  • [15:15] Competition in DBS.
  • [16:45] Initial application of closed-loop DBS is auto-tune.
  • [17:30] Closed-loop can enable therapies.
  • [19:03] Software development in DBS devices.
  • [20:10] Partnerships between medical device companies and AI companies.
  • [21:27] Long-term vision for Rune.

Selected Links

Related Podcasts


Back To Top